GB8830312D0 — Heterocyclic compounds
Assigned to H Lundbeck AS · Expires 1989-02-22 · 37y expired
What this patent protects
The invention relates to novel compounds of the formula: <CHEM> wherein R<1>, R<2>, X and "Ar" are as defined in Claim 1; as well as pharmaceutically acceptable acid addition salts and stereo isomeres thereof. The compounds are described as having centr…
USPTO Abstract
The invention relates to novel compounds of the formula: <CHEM> wherein R<1>, R<2>, X and "Ar" are as defined in Claim 1; as well as pharmaceutically acceptable acid addition salts and stereo isomeres thereof. The compounds are described as having central sterotonin activity with preference for the serotonin 5-HT1A receptors, which indicates usefulness in the treatment of CNS disorders, including anxiety, depression and aggression, or in diseases related to cardiovascular, gastrointestinal and renal systems. Also methods of preparing said compounds and pharmaceutical compositions containing same are described.
Drugs covered by this patent
- Addyi (FLIBANSERIN) · Sprout Pharms
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.